Posted by Michael Wonder on 22 May 2023
FDA approves Ayvakit (avapritinib) as the first and only treatment for indolent systemic mastocytosis
22 May 2023 - Approval based on the positive PIONEER trial, in which once-daily Ayvakit achieved significant improvements in disease symptoms and measures of mast cell burden, with a safety profile that compared favourably to placebo.
Blueprint Medicines today announced that the US FDA has approved Ayvakit (avapritinib) for the treatment of adults with indolent systemic mastocytosis.
